Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: First-in-human results

Science Translational Medicine

Volumn 5, Issue 184, 2013, Pages

  Sturm, Matthew B ^a   Joshi, Bishnu P ^a   Lu, Shaoying ^b   Piraka, Cyrus ^a   Khondee, Supang ^a   Elmunzer, Badih Joseph ^a   Kwon, Richard S ^a   Beer, David G ^c   Appelman, Henry D ^a   Turgeon, Danielle Kim ^a   Wang, Thomas D ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLSERYLTYROSYLASPARAGINYLTYROSYLASPARTYLALANINE FLUORESCEIN ISOTHIOCYANATE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG BINDING; DRUG SAFETY; DRUG SYNTHESIS; ENDOSCOPIC MUCOSAL RESECTION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS DYSPLASIA; EX VIVO STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SQUAMOUS EPITHELIUM; STEREOMICROSCOPY;

ADENOCARCINOMA; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; HUMANS; PEPTIDES;

EID: 84878266233     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004733     Document Type: Article

References (40)

1. Global Cancer Facts & Figures 2nd Edition (American Cancer Society, Atlanta, GA, 2011).
2. L. M. Brown, S. S. Devesa, W. H. Chow, Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J. Natl. Cancer Inst. 100, 1184-1187 (2008).
3. H. Pohl, H. G. Welch, The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J. Natl. Cancer Inst. 97, 142-146 (2005).
4. M. Solaymani-Dodaran, R. F. Logan, J. West, T. Card, C. Coupland, Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 53, 1070-1074 (2004).
5. B. J. Reid, D. S. Levine, G. Longton, P. L. Blount, P. S. Rabinovitch, Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets. Am. J. Gastroenterol. 95, 1669-1676 (2000).
6. American Gastroenterological Association, S. J. Spechler, P. Sharma, R. F. Souza, J. M. Inadomi, N. J. Shaheen, American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 140, 1084-1091 (2011).
7. R. Kariv, T. P. Plesec, J. R. Goldblum, M. Bronner, M. Oldenburgh, T. W. Rice, G. W. Falk, The Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. Clin. Gastroenterol. Hepatol. 7, 653-658 (2009).
8. C. H. Lim, O. Rotimi, S. P. Dexter, A. T. Axon, Randomized crossover study that used methylene blue or random 4-quadrant biopsy for the diagnosis of dysplasia in Barrett 's esophagus. Gastrointest. Endosc. 64, 195-199 (2006).
9. M. Singh, A. Bansal, W. L. Curvers, M. A. Kara, S. B. Wani, L. Alvarez Herrero, C. R. Lynch, M. C. van Kouwen, F. T. Peters, J. D. Keighley, A. Rastogi, K. Pondugula, R. Kim, V. Singh, S. Gaddam, J. J. Bergman, P. Sharma, Observer agreement in the assessment of narrowband imaging system surface patterns in Barrett 's esophagus: A multicenter study. Endoscopy 43, 745-751 (2011).
10. M. A. Kara, F. P. Peters, F. J. Ten Kate, S. J. Van Deventer, P. Fockens, J. J. Bergman, Endoscopic video autofluorescence imaging may improve the detection of early neoplasia in patients with Barrett's esophagus. Gastrointest. Endosc. 61, 679-685 (2005).
11. L. Qiu, D. K. Pleskow, R. Chuttani, E. Vitkin, J. Leyden, N. Ozden, S. Itani, L. Guo, A. Sacks, J. D. Goldsmith, M. D. Modell, E. B. Hanlon, I. Itzkan, L. T. Perelman, Multispectral scanning during endoscopy guides biopsy of dysplasia in Barrett's esophagus. Nat. Med. 16, 603-606 (2010).
12. N. G. Terry, Y. Zhu, M. T. Rinehart, W. J. Brown, S. C. Gebhart, S. Bright, E. Carretta, C. G. Ziefle, M. Panjehpour, J. Galanko, R. D. Madanick, E. S. Dellon, D. Trembath, A. Bennett, J. R. Goldblum, B. F. Overholt, J. T. Woosley, N. J. Shaheen, A. Wax, Detection of dysplasia in Barrett's esophagus with in vivo depth-resolved nuclear morphology measurements. Gastroenterology 140, 42-50 (2011).
13. L. M. Almond, J. Hutchings, N. Shepherd, H. Barr, N. Stone, C. Kendall, Raman spectroscopy: A potential tool for early objective diagnosis of neoplasia in the oesophagus. J. Biophotonics 4, 685-695 (2011).
14. M. J. Gora, J. S. Sauk, R. W. Carruth, K. A. Gallagher, M. J. Suter, N. S. Nishioka, L. E. Kava, M. Rosenberg, B. E. Bouma, G. J. Tearney, Tethered capsule endomicroscopy enables less invasive imaging of gastrointestinal tract microstructure. Nat. Med. 19, 238-240 (2013).
15. L. B. Lovat, K. Johnson, G. D. Mackenzie, B. R. Clark, M. R. Novelli, S. Davies, M. O'Donovan, C. Selvasekar, S. M. Thorpe, D. Pickard, R. Fitzgerald, T. Fearn, I. Bigio, S. G. Bown, Elastic scattering spectroscopy accurately detects high grade dysplasia and cancer in Barrett's oesophagus. Gut 55, 1078-1083 (2006).
16. M. Goetz, A. Ziebart, S. Foersch, M. Vieth, M. J. Waldner, P. Delaney, P. R. Galle, M. F. Neurath, R. Kiesslich, In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor. Gastroenterology 138, 435-446 (2010).
17. J. Liu, X. Zuo, C. Li, T. Yu, X. Gu, C. Zhou, Z. Li, M. Goetz, R. Kiesslich, Y. Li, In vivo molecular imaging of epidermal growth factor receptor in patients with colorectal neoplasia using confocal laser endomicroscopy. Cancer Lett. 330, 200-207 (2013).
18. P. L. Hsiung, J. Hardy, S. Friedland, R. M. Soetikno, C. B. Du, A. P. Wu, P. Sahbaie, J. M. Crawford, A. W. Lowe, C. H. Contag, T. D. Wang, Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat. Med. 14, 454-458 (2008).
19. W. A. Wells, P. E. Barker, C. MacAulay, M. Novelli, R. M. Levenson, J. M. Crawford, Validation of novel optical imaging technologies: The pathologists' view. J. Biomed. Opt. 12, 051801 (2007).
20. M. Li, C. P. Anastassiades, B. Joshi, C. M. Komarck, C. Piraka, B. J. Elmunzer, D. K. Turgeon, T. D. Johnson, H. Appelman, D. G. Beer, T. D. Wang, Affinity peptide for targeted detection of dysplasia in Barrett's esophagus. Gastroenterology 139, 1472-1480 (2010).
21. E. M. Sevick-Muraca, W. J. Akers, B. P. Joshi, G. D. Luker, C. S. Cutler, L. J. Marnett, C. H. Contag, T. D. Wang, A. Azhdarinia, Advancing the translation of optical imaging agents for clinical imaging. Biomed. Opt. Express 4, 160-170 (2013).
22. L. G. Trabuco, S. Lise, E. Petsalaki, R. B. Russell, PepSite: Prediction of peptide-binding sites from protein surfaces. Nucleic Acids Res. 40, W423-W427 (2012).
23. V. Yurchenko, G. Zybarth, M. O'Connor, W. W. Dai, G. Franchin, T. Hao, H. Guo, H. C. Hung, B. Toole, P. Gallay, B. Sherry, M. Bukrinsky, Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J. Biol. Chem. 277, 22959-22965 (2002).
24. M. F. Cheng, C. Tzao, W. C. Tsai, W. H. Lee, A. Chen, H. Chiang, L. F. Sheu, J. S. Jin, Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: Correlation with clinicopathological parameters. Dis. Esophagus 19, 482-486 (2006).
25. J. J. Boonstra, R. van Marion, D. G. Beer, L. Lin, P. Chaves, C. Ribeiro, A. D. Pereira, L. Roque, S. J. Darnton, N. K. Altorki, D. S. Schrump, D. S. Klimstra, L. H. Tang, J. R. Eshleman, H. Alvarez, Y. Shimada, H. van Dekken, H. W. Tilanus, W. N. Dinjens, Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J. Natl. Cancer Inst. 102, 271-274 (2010).
26. L. Lin, C. T. Miller, J. I. Contreras, M. S. Prescott, S. L. Dagenais, R. Wu, J. Yee, M. B. Orringer, D. E. Misek, S. M. Hanash, T. W. Glover, D. G. Beer, The hepatocyte nuclear factor 3 α gene, HNF3α (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res. 62, 5273-5279 (2002).
27. C. T. Miller, S. Aggarwal, T. K. Lin, S. L. Dagenais, J. I. Contreras, M. B. Orringer, T. W. Glover, D. G. Beer, L. Lin, Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas. Cancer Res. 63, 4136-4143 (2003).
28. R. Beroukhim, C. H. Mermel, D. Porter, G. Wei, S. Raychaudhuri, J. Donovan, J. Barretina, J. S. Boehm, J. Dobson, M. Urashima, K. T. Mc Henry, R. M. Pinchback, A. H. Ligon, Y. J. Cho, L. Haery, H. Greulich, M. Reich, W. Winckler, M. S. Lawrence, B. A. Weir, K. E. Tanaka, D. Y. Chiang, A. J. Bass, A. Loo, C. Hoffman, J. Prensner, T. Liefeld, Q. Gao, D. Yecies, S. Signoretti, E. Maher, F. J. Kaye, H. Sasaki, J. E. Tepper, J. A. Fletcher, J. Tabernero, J. Baselga, M. S. Tsao, F. Demichelis,M. A. Rubin, P. A. Janne,M. J. Daly, C. Nucera, R. L. Levine, B. L. Ebert, S. Gabriel, A. K. Rustgi, C. R. Antonescu, M. Ladanyi, A. Letai, L. A. Garraway, M. Loda, D. G. Beer, L. D. True, A. Okamoto, S. L. Pomeroy, S. Singer, T. R. Golub, E. S. Lander, G. Getz,W. R. Sellers, M. Meyerson, The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
29. 2+. J. Am. Chem. Soc. 122, 174-175 (2000).
30. M. B. Aldrich, M. V. Marshall, E. M. Sevick-Muraca, G. Lanza, J. Kotyk, J. Culver, L. V. Wang, J. Uddin, B. C. Crews, L. J. Marnett, J. C. Liao, C. Contag, J. M. Crawford, K. Wang, B. Reisdorph, H. Appelman, D. K. Turgeon, C. Meyer, T. D. Wang, Seeing it through: Translational validation of new medical imaging modalities. Biomed. Opt. Express 3, 764-776 (2012).
31. E. L. Bird-Lieberman, A. A. Neves, P. Lao-Sirieix, M. O'Donovan, M. Novelli, L. B. Lovat, W. S. Eng, L. K. Mahal, K. M. Brindle, R. C. Fitzgerald, Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat. Med. 18, 315-321 (2012).
32. G. M. van Dam, G. Themelis, L. M. Crane, N. J. Harlaar, R. G. Pleijhuis, W. Kelder, A. Sarantopoulos, J. S. de Jong, H. J. Arts, A. G. van der Zee, J. Bart, P. S. Low, V. Ntziachristos, Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-a targeting: First in-human results. Nat. Med. 17, 1315-1319 (2011).
33. Y. Urano, M. Sakabe, N. Kosaka, M. Ogawa, M. Mitsunaga, D. Asanuma, M. Kamiya, M. R. Young, T. Nagano, P. L. Choyke, H. Kobayashi, Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase-activated fluorescent probe. Sci. Transl. Med. 3, 110ra119 (2011).
34. Z. Liu, S. J. Miller, B. P. Joshi, T. D. Wang, In vivo targeting of colonic dysplasia on fluorescence endoscopy with near-infrared octapeptide. Gut 62, 395-403 (2013).
35. M. E. Holbein, J. P. Berglund, Understanding Food and Drug Administration regulatory requirements for an investigational device exemption for sponsor-investigators. J. Investig. Med. 60, 987-994 (2012).
36. P. Sharma, J. Dent, D. Armstrong, J. J. Bergman, L. Gossner, Y. Hoshihara, J. A. Jankowski, O. Junghard, L. Lundell, G. N. Tytgat, M. Vieth, The development and validation of an endoscopic grading system for Barrett's esophagus: The Prague C & M criteria. Gastroenterology 131, 1392-1399 (2006).
37. G. B. Fields, R. L. Noble, Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35, 161-214 (1990).
38. M. Vodnik, U. Zager, B. Strukelj, M. Lunder, Phage display: Selecting straws instead of a needle from a haystack. Molecules 16, 790-817 (2011).
39. 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues. Clin. Exp. Metastasis 26, 105-119 (2009).
40. L. L. Kiessling, J. E. Gestwicki, L. E. Strong, Synthetic multivalent ligands in the exploration of cell-surface interactions. Curr. Opin. Chem. Biol. 4, 696-703 (2000).